Case-Based Roundtable Meetings Spotlight: March 2022

During a Targeted Oncology case-based roundtable event, Timothy Kuzel, MD, discussed risk assessment and later-line treatment options for a patient diagnosed with metastatic renal cell carcinoma who received lenvatinib and pembrolizumab.

During a Targeted Oncology case-based roundtable event, Arlene Siefker-Radtke discussed the second-line treatment options for a patient with urothelial carcinoma and the EV-301 trial of enfortumab vedotin.

During a Targeted Oncology case-based roundtable event, Sumit Madan, MD, discussed the case of a 55-year-old patient with multiple myeloma who was refractory to multiple lines of therapy.

During a Targeted Oncology case-based roundtable event, Martin Dietrich, MD, PhD, discussed the MonarchE trial of abemaciclib and the agent's use in high-risk, early-stage breast cancer.

During a Targeted Oncology case-based roundtable discussion, Javier Pinilla-Ibarz, MD, PhD, discusses risk factors and prophylactic options for tumor lysis syndrome.

During a Targeted Oncology case-based roundtable event, Ajay K. Gopal, MD, discussed the options for second-line and subsequent treatment of a patient with relapsed/refractory diffuse large B-cell lymphoma who refuses CAR T-cell therapy.

During a Targeted Oncology case-based roundtable event, Erin Crane, MD, MPH, discussed several phase 3 trials of new combinations for maintenance therapy of advanced ovarian cancer.

During a Targeted Oncology case-based roundtable event, Claudine Isaacs, MD, discussed treatment options for a patient with triple-negative breast cancer whose condition worsened after first-line gemcitabine plus carboplatin.

During a Targeted Oncology case-based roundtable event, Rachel B. Salit, MD, discussed the case of a patient with acute graft versus host disease, steroid dependence, and therapy for steroid-refractory disease.

During a Targeted Oncology case-based roundtable event, Jad Chahoud, MD, MPH, discussed the case of a patient who progresses while on pembrolizumab plus axitinib, then again while on cabozantinib.

During a Targeted Oncology case-based roundtable event, Richard S. Finn, MD, discussed the frontline treatment options for a patient with hepatocellular carcinoma.

During a Targeted Oncology case-based roundtable event, David P. Carbone, MD, PhD, discussed molecular testing and treatment for a patient with late-stage non–small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Luciano J. Costa, MD, PhD, discussed various treatment regiments for a patient with newly diagnosed multiple myeloma.